• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病进程中的血浆淀粉样蛋白水平及其与中枢生物标志物的相关性。

Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.

机构信息

Memory Resource and Research Centre of de Paris-Broca-Ile de France, Hopital Broca, APHP, Paris, France; EA 4468, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Memory Resource and Research Centre of de Paris-Broca-Ile de France, Hopital Broca, APHP, Paris, France; EA 4468, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

出版信息

Alzheimers Dement. 2018 Jul;14(7):858-868. doi: 10.1016/j.jalz.2018.01.004. Epub 2018 Feb 17.

DOI:10.1016/j.jalz.2018.01.004
PMID:29458036
Abstract

INTRODUCTION

Diagnostic relevance of plasma amyloid β (Aβ) for Alzheimer's disease (AD) process yields conflicting results. The objective of the study was to assess plasma levels of Aβ and Aβ in amnestic mild cognitive impairment (MCI), nonamnestic MCI, and AD patients and to investigate relationships between peripheral and central biomarkers.

METHODS

One thousand forty participants (417 amnestic MCI, 122 nonamnestic MCI, and 501 AD) from the Biomarker of AmyLoïd pepTide and AlZheimer's diseAse Risk multicenter prospective study with cognition, plasma, cerebrospinal fluid (CSF), and magnetic resonance imaging assessments were included.

RESULTS

Plasma Aβ and Aβ were lower in AD (36.9 [11.7] and 263 [80] pg/mL) than in amnestic MCI (38.2 [11.9] and 269 [68] pg/mL) than in nonamnestic MCI (39.7 [10.5] and 272 [52] pg/mL), respectively (P = .01 for overall difference between groups for Aβ and P = .04 for Aβ). Globally, plasma Aβ correlated with age, Mini-Mental State Examination, and APOE ε4 allele. Plasma Aβ correlated with all CSF biomarkers in MCI but only with CSF Aβ in AD.

DISCUSSION

Plasma Aβ was associated with cognitive status and CSF biomarkers, suggesting the interest of plasma amyloid biomarkers for diagnosis purpose.

摘要

简介

血浆淀粉样蛋白 β(Aβ)对阿尔茨海默病(AD)进程的诊断相关性产生了相互矛盾的结果。本研究的目的是评估 AD 患者、遗忘型轻度认知障碍(MCI)患者和非遗忘型 MCI 患者的血浆 Aβ 和 Aβ 水平,并探讨外周和中枢生物标志物之间的关系。

方法

来自多中心前瞻性研究的 1040 名参与者(417 名遗忘型 MCI、122 名非遗忘型 MCI 和 501 名 AD),进行认知、血浆、脑脊液(CSF)和磁共振成像评估,纳入本研究。

结果

与遗忘型 MCI(38.2 [11.9] pg/mL 和 269 [68] pg/mL)相比,AD 患者的血浆 Aβ 和 Aβ 水平较低(36.9 [11.7] pg/mL 和 263 [80] pg/mL)(P <.01),与非遗忘型 MCI 相比,AD 患者的血浆 Aβ 和 Aβ 水平也较低(39.7 [10.5] pg/mL 和 272 [52] pg/mL)(P <.04)。总体而言,血浆 Aβ 与年龄、简易精神状态检查和 APOE ε4 等位基因相关。在 MCI 中,血浆 Aβ 与所有 CSF 生物标志物相关,但在 AD 中仅与 CSF Aβ 相关。

讨论

血浆 Aβ 与认知状态和 CSF 生物标志物相关,表明血浆淀粉样蛋白生物标志物在诊断目的上具有重要意义。

相似文献

1
Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.阿尔茨海默病进程中的血浆淀粉样蛋白水平及其与中枢生物标志物的相关性。
Alzheimers Dement. 2018 Jul;14(7):858-868. doi: 10.1016/j.jalz.2018.01.004. Epub 2018 Feb 17.
2
The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.血浆 Aβ 水平与轻度认知障碍老年人痴呆的关系。
J Neurol Sci. 2011 Jun 15;305(1-2):92-6. doi: 10.1016/j.jns.2011.03.005. Epub 2011 Mar 26.
3
Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.埃尔朗根评分作为预测阿尔茨海默病轻度认知障碍向痴呆进展的工具。
Alzheimers Res Ther. 2019 Jan 5;11(1):2. doi: 10.1186/s13195-018-0456-x.
4
Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.基于血浆生物标志物预测轻度认知障碍患者的纵向认知下降和阿尔茨海默病转化。
Cells. 2024 Jun 22;13(13):1085. doi: 10.3390/cells13131085.
5
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.载脂蛋白 E 基因型与阿尔茨海默病脑脊液生物标志物的诊断准确性。
JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.
6
The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.EMIF-AD 多模态生物标志物发现研究:设计、方法和队列特征。
Alzheimers Res Ther. 2018 Jul 6;10(1):64. doi: 10.1186/s13195-018-0396-5.
7
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.生物标志物组合对预测轻度认知障碍向阿尔茨海默病痴呆进展的增量价值。
Alzheimers Res Ther. 2017 Oct 10;9(1):84. doi: 10.1186/s13195-017-0301-7.
8
Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia.生物标志物组合对轻度认知障碍向阿尔茨海默病转化的预测价值增加。
Transl Neurodegener. 2020 Aug 3;9(1):30. doi: 10.1186/s40035-020-00210-5.
9
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.遗忘型和非遗忘型 MCI 患者阿尔茨海默病的预测。
Neurology. 2013 Mar 19;80(12):1124-32. doi: 10.1212/WNL.0b013e318288690c. Epub 2013 Feb 27.
10
Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.血浆 Aβ42/40 比值可检测阿尔茨海默病早期,并与 AB255 研究中的 CSF 和神经影像学生物标志物相关联。
J Prev Alzheimers Dis. 2019;6(1):34-41. doi: 10.14283/jpad.2018.41.

引用本文的文献

1
Bead-based microfluidic platforms for multiplex and ultrasensitive immunoassays in clinical diagnosis and treatment.用于临床诊断和治疗中多重及超灵敏免疫测定的基于微珠的微流控平台。
Mechanobiol Med. 2024 Mar 16;2(2):100063. doi: 10.1016/j.mbm.2024.100063. eCollection 2024 Jun.
2
Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers.阿尔茨海默病血液生物标志物的认知表型分析与解读
JAMA Neurol. 2025 May 1;82(5):506-515. doi: 10.1001/jamaneurol.2025.0142.
3
Blood-based biomarker prescreening with different testing combinations and cutoffs: A simulation study examining efficacy and cost-effectiveness in Alzheimer's disease prevention studies.
基于血液的生物标志物预筛查:不同检测组合及临界值的模拟研究——一项关于阿尔茨海默病预防研究中有效性和成本效益的考察
Alzheimers Dement (N Y). 2025 Mar 10;11(1):e70065. doi: 10.1002/trc2.70065. eCollection 2025 Jan-Mar.
4
Plasma biomarkers for diagnosis and differentiation and their cognitive correlations in patients with Alzheimer's disease.阿尔茨海默病患者诊断与鉴别诊断的血浆生物标志物及其认知相关性
Brain Commun. 2025 Feb 25;7(2):fcaf094. doi: 10.1093/braincomms/fcaf094. eCollection 2025.
5
Polyamine biosynthesis dysregulation in Alzheimer's disease and Down syndrome cellular models.阿尔茨海默病和唐氏综合征细胞模型中的多胺生物合成失调
bioRxiv. 2025 Feb 2:2025.01.31.635912. doi: 10.1101/2025.01.31.635912.
6
Hypertension moderates the relationship between plasma beta-amyloid and cognitive impairment: a cross-sectional study in Xi'an, China.高血压调节血浆β-淀粉样蛋白与认知障碍之间的关系:中国西安的一项横断面研究。
Front Aging Neurosci. 2025 Jan 28;17:1532676. doi: 10.3389/fnagi.2025.1532676. eCollection 2025.
7
Amyloid-β can activate JNK signalling via WNT5A-ROR2 to reduce synapse formation in Alzheimer's disease.淀粉样蛋白β可通过WNT5A-ROR2激活JNK信号通路,以减少阿尔茨海默病中的突触形成。
J Cell Sci. 2025 Feb 1;138(3). doi: 10.1242/jcs.263526. Epub 2025 Feb 5.
8
Preliminary reference values for Alzheimer's disease plasma biomarkers in Congolese individuals with and without dementia.刚果有或无痴呆症个体中阿尔茨海默病血浆生物标志物的初步参考值。
Front Aging Neurosci. 2024 Nov 21;16:1477047. doi: 10.3389/fnagi.2024.1477047. eCollection 2024.
9
Fast Declining Prediction in Alzheimer's Disease from Early Clinical Assessment.基于早期临床评估的阿尔茨海默病快速衰退预测
Curr Neuropharmacol. 2025;23(5):602-611. doi: 10.2174/011570159X332930240925095423.
10
Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease.厘清脑脊液 Aβ、tau、BACE1 和神经颗粒蛋白与阿尔茨海默病 AT(N)分期的关系。
Mol Neurodegener. 2024 Oct 8;19(1):66. doi: 10.1186/s13024-024-00755-3.